Goserelin for Advanced Ovarian Cancer
Author Information
Author(s): M.J. Lind, B.M.J. Cantwell, M.J. Millward, A. Robinson, M. Proctor, D. Simmons, J. Carmichael, A.L. Harris
Primary Institution: University Department of Clinical Oncology, Regional Radiotherapy Centre, Newcastle General Hospital
Hypothesis
Goserelin might exert its anti-proliferative effect in epithelial ovarian cancer due to a direct action on tumor cells and/or by lowering circulating estrogen and androgen levels.
Conclusion
Goserelin treatment resulted in disease stabilization for 6 months or more in 23% of patients with advanced epithelial ovarian cancer.
Supporting Evidence
- Two patients achieved a partial remission lasting 40 and 105 weeks.
- Five patients had disease stabilization lasting between 25 and 70 weeks.
- Twenty-three patients had progressive disease, including five early deaths.
Takeaway
Doctors tested a drug called goserelin on women with a type of cancer that came back after treatment, and it helped some of them feel better for a while.
Methodology
Women with relapsed epithelial ovarian cancer were treated with monthly goserelin injections and evaluated for response and toxicity.
Limitations
The study included patients who were heavily pre-treated and had advanced cancers, which may limit the generalizability of the results.
Participant Demographics
Median age was 57.5 years, with a range from 38 to 90 years; most had received prior chemotherapy.
Statistical Information
Confidence Interval
10-42%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website